<DOC>
	<DOCNO>NCT01641991</DOCNO>
	<brief_summary>A Phase IV , randomize , multicenter trial ass immunogenicity safety BioThrax® vary dose regimen primary objective obtain information possible dose-sparing strategy event major biothreat .</brief_summary>
	<brief_title>Assessment Immunogenicity Safety Dose-Sparing BioThrax® AVA Schedule</brief_title>
	<detailed_description>This Phase IV , randomize , open-label immunogenicity safety study evaluate four dose regimen BioThrax® Post-Exposure Prophylaxis ( PEP ) anthrax . BioThrax® administer subcutaneous ( SC ) injection primary series administer intramuscular ( IM ) injection boost . The four dosing regimen : 0.50mL BioThrax® Days 0 , 14 , 6 month boost ; 0.50mL BioThrax® Days 0 , 28 6 month boost ; 0.50mL BioThrax® Days 0 , 14 , 28 6 month boost 0.25mL BioThrax® Days 0 , 14 , 28 , 6 month boost 0.50ml IM Approximately 300 subject randomize 1:1:1:1 one four study arm . Enrollment stratify gender , approximately equal number male female ( 18 65 year ) enrol dose regimen . The Primary objective evaluate immunogenicity four dosing regimen BioThrax® use Toxin Neutralization Assay ( TNA ) . The secondary objective evaluate safety four dosing regimen BioThrax® .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<criteria>Subject able provide inform consent ; Female male , 18 65 year age , inclusive ; If subject female childbearing potential , agree practice abstinence sexual intercourse men ( vaginal penetration penis , coitus ) use acceptable contraception , initiate least 30 day prior first study vaccination 56 day 6 month boost vaccination order avoid pregnancy : 1 . A woman consider childbearing potential unless postmenopausal ( &gt; /= 1 year without menses ) surgically sterilize ( tubal ligation , bilateral oophorectomy , hysterectomy ) 2 . Acceptable contraception method restrict effective device ( IUDs , NuvaRing® ) license hormonal product use method minimum 30 day prior vaccination , condom spermicidal agent , monogamous relationship vasectomize partner vasectomize 6 month prior study entry , successful Essure placement document confirmation test least 3 month procedure , Food Drug Administration ( FDA ) approve contraceptive method Be willing able return visit blood collection duration study ; Be able understand comply plan study procedure ; Agree complete memory aid report concomitant medication Adverse Events study period . Further clarification inclusion/exclusion criterion : Provided subject meet study inclusion criterion none study exclusion criterion , follow condition exclude subject study participation : History gestational diabetes ; Type II diabetes control diet oral hypoglycemic medication ; Treated , control , uncomplicated hypertension ; History coronary artery disease , asymptomatic ( New York Heart Association [ NYHA ] Function Class I ) , stable medical regimen . Persons meet criterion must least two year postmyocardial infarction , cardiac bypass surgery and/or percutaneous coronary intervention ( e.g. , angioplasty , stent placement ) order qualify . Persons history cardiac disease must care physician ; Cured , nonmetastatic cancer ( exclude hematologic malignancy ) , diseasefree five year ; Localized skin cancer , resect ( include squamous cell basal cell carcinoma ) . Participants history melanoma must diseasefree five year ; Exerciseinduced bronchospasm control inhaled medication ( ) ; Mild asthma : Subjects hospitalize asthma past two year use inhaler control symptom eligible . Only low medium dos inhaled steroid , define &lt; /=3 puff day , allow . Persons require oral parenteral steroid eligible . Subjects isolated entrapment neuropathy , carpal tunnel syndrome , compression neuropathy , lumbar radiculopathy , associate systemic disease immune dysfunction may eligible enrollment . If subject 's condition stable six month , surgery plan condition , neurologic examination normal ( specifically weakness paresthesia ) , mononeuropathy interfere assessment reactogenicity , subject eligible . Subjects vitiligo otherwise healthy vitiligo widespread area vaccination may eligible enrollment . Subjects seasonal allergy eligible provide dose nasal steroid use &lt; 800µg/day . Have prior history anthrax immunization anthrax ; Intend enlist military study ; Have know allergy aluminum hydroxide , formaldehyde , benzethonium chloride , latex ; ( Females ) Be pregnant , plan become pregnant time Screening Visit 56 day 6 month boost vaccination , refuse use/not use acceptable method birth control ( see Inclusion Criterion 3 ) 30 day prior first study vaccine dose 56 day 6 month boost vaccination ; Have receive experimental product within 30 day study entry plan receive experimental product time study ; Have receive live vaccine within 30 day study entry plan receive live vaccine prior Day 63 study within 30 day 6 month boost ; Have receive inactivated vaccine within 14 day study entry plan receive inactivated vaccine Day 0 Day 42 within 14 day 6 month boost ; Have receive immunosuppressive therapy ( include systemic steroid ) within 3 month prior study entry plan receive immunosuppressive therapy time study ; Have receive cytotoxic therapy previous 5 year plan receive cytotoxic therapy time study ; Have receive parenteral immunoglobulin blood product within 3 month study plan receive parenteral immunoglobulin blood product time study ; Have history GuillainBarré Syndrome ; Have active malignancy history metastatic hematologic malignancy ; Have Type I diabetes Type II diabetes treated insulin ; Have cardiovascular disease ( include person history cardiomyopathy congestive heart failure ) ; Have moderate severe asthma , chronic obstructive pulmonary disease significant pulmonary disease ; Have hepatic renal insufficiency ; Have autoimmune , inflammatory , vasculitic rheumatic disease include limited systemic lupus erythematosus , polymyalgia rheumatica , rheumatoid arthritis scleroderma ; Have HIV , hepatitis B hepatitis C infection ; Have condition know produce associated immunosuppression ; Have neuropathy evolve neurological condition ; Have ongoing drug abuse/dependence ( include alcohol ) issue history issue within five year enrollment ; Have seizure disorder ; Have moderate severe illness and/or oral temperature &gt; 100.4 F within 3 day prior vaccination ; Have blood pressure , heart rate respiratory rate Grade 2 high ; Have chronic condition , opinion Investigator , would render vaccination unsafe would interfere study evaluation completion study ; Have total White Blood Cell ( WBC ) count , Absolute Neutrophil Count ( ANC ) , hemoglobin platelet count Grade 2 high ; Have creatinine high normal range ; Have Alanine Aminotransferase ( ALT ) &gt; /= 1.2 x Upper Limit Normal ; Have value high trace glucose and/or protein urinalysis ; Have history hospitalization psychiatric illness , suicide attempt , confinement danger self others , within past 10 year . ( Subjects psychiatric disorder [ meeting exclusion criterion , e.g . attentiondeficit hyperactivity disorder ] control minimum 3 month investigator determine subject 's mental status compromise subject 's ability comply protocol requirement may enrol ) ; Be take follow psychiatric drug : aripiprazole , clozapine , ziprasidone , haloperidol , molindone , loxapine , thioridazine , thiothixene , pimozide , fluphenazine , risperidone , mesoridazine , quetiapine , trifluoperazine , trifluopromazine , chlorprothixene , chlorpromazine , perphenazine , olanzapine , carbamazepine , divalproex sodium , lithium carbonate lithium citrate ; Be take one antidepressant drug include list ( subject take one antidepressant drug [ list exclude psychiatric drug ] stable least 3 month prior enrollment without decompensating allow enrollment study provide investigator determines subject 's mental status compromise subject 's ability comply protocol requirement ) ; Have donate blood within 30 day enrollment plan donate blood study . Have tattoo area vaccination site interfere assessment injection site reactogenicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Bacillus anthracis , anthrax , vaccine , BioThrax® , dose-sparing</keyword>
</DOC>